



Brussels, 28.4.2023
C(2023) 3036 final

COMMISSION IMPLEMENTING DECISION

of 28.4.2023

**amending the marketing authorisation granted by Decision C(2022) 2308(final) for
“Breyanzi - lisocabtagene maraleucel”, a medicinal product for human use**

(Text with EEA relevance)

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

COMMISSION IMPLEMENTING DECISION

of 28.4.2023

**amending the marketing authorisation granted by Decision C(2022) 2308(final) for
“Breyanzi - lisocabtagene maraleucel”, a medicinal product for human use**

(Text with EEA relevance)

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency¹,

Having regard to Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products², and in particular Article 17(2) thereof,

Having regard to the changes to the terms of the decision granting the marketing authorisation requested by Bristol Myers Squibb Pharma EEIG in accordance with Regulation (EC) No 1234/2008,

Having regard to the opinion of the European Medicines Agency, formulated on 30 March 2023 by the Committee for Medicinal Products for Human Use,

Whereas:

- (1) The European Medicines Agency's opinion is favourable to the variation of the terms of the decision granting the marketing authorisation as submitted by the marketing authorisation holder.
- (2) Decision C(2022) 2308(final) should therefore be amended accordingly. The Union Register of Medicinal Products should also be updated.
- (3) For the sake of clarity and transparency, it is appropriate, following the amendment of part or parts of the Annexes, to provide for a consolidated version thereof. The Annexes to Decision C(2022) 2308(final) should therefore be replaced.

¹ OJ L 136, 30.4.2004, p. 1.

² OJ L 334, 12.12.2008, p. 7.

HAS ADOPTED THIS DECISION:

Article 1

Decision C(2022) 2308(final) is amended as follows:

- 1) Annex I is replaced by the text set out in Annex I to this Decision;
- 2) Annex II is replaced by the text set out in Annex II to this Decision;
- 3) Annex III is replaced by the text set out in Annex III to this Decision.

Article 2

This Decision is addressed to Bristol Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland.

Done at Brussels, 28.4.2023

For the Commission

Sandra GALLINA

Director-General

